Status:
COMPLETED
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dos...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Unresectable Stage III or Stage IV melanoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion
- Brain metastases with symptoms or requiring treatment
- History of autoimmune disease
Key Trial Info
Start Date :
February 17 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 17 2017
Estimated Enrollment :
831 Patients enrolled
Trial Details
Trial ID
NCT01515189
Start Date
February 17 2012
End Date
August 17 2017
Last Update
July 31 2019
Active Locations (88)
Enter a location and click search to find clinical trials sorted by distance.
1
The Angeles Clinic And Research Institute
Los Angeles, California, United States, 90025
2
University Of California Los Angeles
Los Angeles, California, United States, 90095
3
Baptist Cancer Institute
Jacksonville, Florida, United States, 32207
4
Orlando Health, Inc
Orlando, Florida, United States, 32806